宜明昂科-B：Promising results of IMM01 released at ASCO

M N 7 Jun 2024 CMB International Global Markets | Equity Research | Company Report ImmuneOnco (1541.HK) Promising results of IMM01 released at ASCO NOT RATED ImmuneOnco is a clinical-stage biotech company focusing on innate immune Current Price HK$14.44 systems. It has built a differentiated CD47-based portfolio with favourable safety and efficacy profiles. The Company has a rich pipeline with 8 drug candidates in China Healthcare clinical studies. The key product asset Timdarpacept (IMM01), a SIRPα-Fc Fusi ...